The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of WNT/B-catenin alterations and metastasis location among patients with metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI) combinations.
 
Javier Ros Montañá
Honoraria - Amgen
Speakers' Bureau - Sanofi
Travel, Accommodations, Expenses - Amgen; Amgen; Merck; Pierre Fabre; SERVIER
 
Iosune Baraibar
Travel, Accommodations, Expenses - Amgen; Merck; SERVIER
 
Victor Navarro Garces
No Relationships to Disclose
 
Nadia Saoudi Gonzalez
Speakers' Bureau - AMGEN
 
Sharela Vega
No Relationships to Disclose
 
Sergio Bueno
No Relationships to Disclose
 
Ariadna Garcia
No Relationships to Disclose
 
Francesc Salva
Honoraria - Amgen; Merck Serono; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Amgen
 
Raquel Comas
No Relationships to Disclose
 
Marta Rodríguez Castells
Speakers' Bureau - Pierre Fabre; Rovi
Travel, Accommodations, Expenses - Amgen; BMS GmbH & Co. KG; Merck
 
Omar Saavedra
No Relationships to Disclose
 
Guzman Alonso
No Relationships to Disclose
 
Elena Garralda
Employment - Next Oncology
Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Incyte; Janssen; MAB Discovery; Roche; Sanofi; Seagen; Thermo Fisher Scientific
Speakers' Bureau - Lilly; MSD; Novartis; Roche; Seagen; Thermo Fisher Scientific
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Janssen (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)
Other Relationship - Adaptimmune (Inst); Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bioinvent (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Catalym (Inst); Cyclacel (Inst); CytomX Therapeutics (Inst); Cytovation (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); HiFiBiO Therapeutics (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Replimune (Inst); Ribon Therapeutics (Inst); Roche (Inst); Ryvu Therapeutics (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); SQZ Biotech (Inst); Symphogen (Inst); T-Knife (Inst); Taiho Pharmaceutical (Inst)
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Cardiff Oncology; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc; Tolremo
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Ana Vivancos
Stock and Other Ownership Interests - Reveal Genomics
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Guardant Health; Incyte; Merck; Roche
Research Funding - Bristol Meyers Squibb (Inst); Incyte (Inst); Roche (Inst)
 
Elena Elez
Honoraria - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche; Sanofi/Aventis; Seagan; SERVIER
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; Bristol Myers Squibb; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); Genentech (Inst); HalioDx (Inst); Hutchison MediPharma (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Roche; Sanofi; SERVIER